Abstract
Ornithine decarboxylase (ODC), the first enzyme in the biosynthesis of polyamines, has increased activity in breast cancer tissue compared with benign and normal tissues. The ODC gene contains a single nucleotide polymorphism in which a guanine is substituted for an adenine. This study investigated whether the ODC +316 G > A polymorphism (rs2302615) was associated with the risk of developing breast cancer. A case–control study involving 121 controls, without breast cancer, 46 patients with breast cancer but without a family history, and 130 breast cancer cases with a family history of breast cancer was conducted. A nested PCR-restriction fragment length polymorphism procedure and the TaqMan 5′ nuclease assay was used to genotype individuals. Risk was significantly lower for heterozygote (GA genotype) individuals [odds ratio (OR) = 0.39, 95% confidence interval (CI) 0.17–0.86, P = 0.018], or individuals with at least one A allele (OR = 0.44, 95% CI 0.21–0.92, P = 0.027), without family history. This protective effect of having at least one copy of the variant A allele was not as strong, however, in those with a family history of the disease. In sporadic breast cancer, the presence of at least one A allele is protective against the disease. The influence of this polymorphism may be less important in individuals with an inherited breast cancer predisposition.
Similar content being viewed by others
References
Wallace HM, Fraser AV, Hughes A (2003) A perspective of polyamine metabolism. Biochem J 376:1–14. doi:10.1042/BJ20031327
Fair WR, Wehner N, Brorsson U (1975) Urinary polyamine levels in the diagnosis of carcinoma of the prostate. J Urol 114:88–92
Kingsnorth AN, Wallace HM, Bundred NJ, Dixon JM (1984) Polyamines in breast cancer. Br J Surg 71:352–356. doi:10.1002/bjs.1800710513
Kingsnorth AN, Lumsden AB, Wallace HM (1984) Polyamines in colorectal cancer. Br J Surg 71:791–794. doi:10.1002/bjs.1800711019
Loser C, Folsch UR, Paprotny C, Creutzfeldt W (1990) Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Pancreas 5:119–127
Tabib A, Bachrach U (1998) Polyamines induce malignant transformation in cultured NIH 3T3 fibroblasts. Int J Biochem Cell Biol 30:135–146. doi:10.1016/S1357-2725(97)00073-3
Takigawa M, Enomoto M, Nishida Y et al (1990) Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res 50:4131–4138
Jasnis MA, Klein S, Monte M et al (1994) Polyamines prevent DFMO-mediated inhibition of angiogenesis. Cancer Lett 79:39–43. doi:10.1016/0304-3835(94)90060-4
Canizares F, Salinas J, de las Heras M et al (1999) Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res 5:2035–2041
Kingsnorth AN, Wallace HM (1985) Elevation of monoacetylated polyamines in human breast cancers. Eur J Cancer Clin Oncol 21:1057–1062. doi:10.1016/0277-5379(85)90291-3
Manni A, Washington S, Griffith JW et al (2002) Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19:95–105. doi:10.1023/A:1014536909007
Kubota S, Yamada T, Kamei S, Seyama Y (1995) Ornithine decarboxylase is directly involved in mouse mammary carcinoma cell invasion in vitro. Biochem Biophys Res Commun 208:1106–1115. doi:10.1006/bbrc.1995.1448
Manni A, Mauger D, Gimotty P, Badger B (1996) Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 2:1901–1906
Manni A, Grove R, Kunselman S, Aldaz M (1995) Involvement of the polyamine pathway in breast cancer progression. Cancer Lett 92:49–57. doi:10.1016/0304-3835(95)03763-M
Radford DM, Nakai H, Eddy RL et al (1990) Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Cancer Res 50:6146–6153
Guo Y, Harris RB, Rosson D et al (2000) Functional analysis of human ornithine decarboxylase alleles. Cancer Res 60:6314–6317
Sharp L, Little J, Schofield AC et al (2002) Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 181:65–71. doi:10.1016/S0304-3835(02)00030-7
Visvanathan K, Helzlsouer KJ, Boorman DW et al (2004) Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 171:652–655. doi:10.1097/01.ju.0000108384.74718.73
Martinez ME, O’Brien TG, Fultz KE et al (2003) Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 100:7859–7864. doi:10.1073/pnas.1332465100
Barry ELR, Baron JA, Bhat S et al (2006) Ornithine decarboxylase modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 98:1494–1500. doi:10.1571/cs4-6-06cc
Pegg AE (2006) Regulation of ornithine decarboxylase. J Biol Chem 281:14529–14532. doi:10.1074/jbc.R500031200
Acknowledgments
We would like to thank Professor Thomas O’Brien for providing us with positive control DNA for the polymorphic alleles and also the Department of Medical Genetics, NHS Grampian, for providing DNA samples from breast cancer patients with a known family history of the disease. We also thank Dr Linda Sharp and Jonathan Baird for collecting and extracting DNA from mouthwash samples. We are grateful to NHS Grampian Endowments for financial assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brown, I., Halliday, S., Greig, H. et al. Genetic polymorphism in ornithine decarboxylase and risk of breast cancer. Familial Cancer 8, 307–311 (2009). https://doi.org/10.1007/s10689-009-9237-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-009-9237-9